Chemomab Therapeutics
Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases
StartupChemomab Therapeutics is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2011. Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases. The company has raised a total of $90.5M across 7 funding rounds, currently at the Public stage. Chemomab Therapeutics was founded by Adi Mor. Key investors include OrbiMed, Sphera Global Healthcare Fund, HBM Healthcare Investments, among 12 total investors. The company has 11-50 employees. Core technologies: Biologicals.
With $90.5M in total funding, Chemomab Therapeutics is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$10M
- OrbiMed
- Sphera Global Healthcare Fund
- HBM Healthcare Investments
12 investors total
Adi MorCo-founder, CEO & CSO
107 articles covered by sources including finance.yahoo.com,
en.globes.co.il,
www.globes.co.il,
www.prnewswire.com,
www.globenewswire.com.
What does Chemomab Therapeutics do?
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury. A global Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with a top-line data readout targeted for the second half of 2024.
How much funding has Chemomab Therapeutics raised?
Chemomab Therapeutics has raised $90.5M in total funding across 7 rounds. The company is currently at the Public stage. Key investors include OrbiMed, Sphera Global Healthcare Fund, HBM Healthcare Investments.
Who founded Chemomab Therapeutics?
Chemomab Therapeutics was founded in 2011 by Adi Mor (Co-founder, CEO & CSO).
What sector is Chemomab Therapeutics in?
Chemomab Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.
Where is Chemomab Therapeutics located?
Chemomab Therapeutics is based in Kiryat Atidim, Tel Aviv-Yafo, Israel, Center District.